The discriminant pattern of pleural fluid inflammatory mediators between tuberculosis and other causes of exudative pleural effusion

Running title: **Inflammatory mediators in pleural tuberculosis**

Vinícius da Cunha Lisboa¹, Raquel da Silva Corrêa¹, Marcelo Ribeiro-Alves², Isabelle Ramos Lopes¹, Thiago Thomaz Mafort³, Ana Paula Gomes dos Santos³, Thaís Porto Amadeu¹, Rogério Lopes Rufino Alves³, Luciana Silva Rodrigues^{1*}

¹ Laboratory of Immunopathology, Medical Science Faculty, Rio de Janeiro State University (UERJ), Rio de Janeiro, RJ, Brazil; ² Laboratory of Clinical Research on STD/AIDS, National Institute of Infectology Evandro Chagas, Oswaldo Cruz Institute (FIOCRUZ), Rio de Janeiro, RJ, Brazil; ³ Department of Pulmonary and Tisiology Care, Pedro Ernesto University Hospital (HUPE)/UERJ, Rio de Janeiro, RJ, Brazil.

* Corresponding author

E-mail: lrodrigues.uerj@gmail.com

ABSTRACT

Pleural tuberculosis (PITB), a form of extrapulmonary TB, remains as a challenge in the diagnosis among many causes of pleural effusion. We recently reported that the combinatorial analysis of interferon-gamma (IFN- γ), IFN- γ -inducible protein 10 (IP-10), and adenosine deaminase (ADA) from the pleural microenvironment was useful to distinguish pleural effusion caused by TB (microbiologically or not confirmed cases) among other etiologies. In this prospective cohort study, a set of inflammatory mediators was quantified in blood and pleural fluid (PF) from exudative pleural effusion cases, including PITB (n = 22) and non-PITB (NTB; n = 17) patients. The levels of IL-2, IL-4, IL-6, IL-10, IL-17A, IFN- γ , TNF, IP-10, TGF- β 1, and ADA were measured and a principal component analysis was applied in order to identify the mediators who contributed most for the variance in data. IFN- γ , IP-10, TNF, TGF- β , and ADA quantified in PF showed significantly higher concentrations in PITB patients when compared to NTB ones. When blood and PF were compared, we have identified significantly higher concentrations of IL-6 and IL-10 in PF, in both groups. TGF- β , solely, showed significantly increased levels in PF and blood from PITB when both clinical specimens were compared to NTB patients. Principal components analysis from PF revealed that the ADA, IP-10, TGF- β , and IFN- γ contributed most for the discriminatory capacity between TPIB and NTB. Our findings showed that important inflammatory mediators in PF may discriminate TB cases from other causes of exudative effusion, the main diseases considered in the differential diagnosis of PITB.

KEYWORDS: pleural tuberculosis, pleural effusion, adenosine deaminase, cytokines in pleural effusion

INTRODUCTION

Tuberculosis, caused by *Mycobacterium tuberculosis* (Mtb), is currently endemic in the world and represents an important public health problem every year. Globally, in 2017, more than 10 million new cases of TB were reported with an estimated 1.3 million deaths. Among infectious diseases, TB is the leading cause of death from a single agent, surpassing the human immunodeficiency virus (HIV) infection (1). Although TB affects mainly the lungs, extrapulmonary forms can appear as an initial manifestation in approximately 25% of adults with TB, of which the pleural space is the second site of involvement followed only by the lymph nodes (2). In Brazil, a high burden TB country, PTB is responsible for more than 40% of cases among many clinical sites of extrapulmonary TB (3) and still imposes a challenging diagnosis due to, mainly, its paucibacillary nature and the need of invasive procedures (4).

Cellular immune response (Th1 immunity) involving CD4⁺ T-lymphocytes, classically studied and associated with the containment of Mtb in pulmonary parenchymal TB, is also predominant in TB pleuritis, which is confirmed by the higher levels of interferon-gamma (IFN- γ) and other inflammatory cytokines (e.g., IL-12) in pleural fluid in comparison to peripheral blood (2, 5–7). IFN- γ promotes cell differentiation, stimulates an increased phagocytic activity and intermediate nitrogen and oxygen species production, which are bactericidal and participate in resistance to Mtb infection (8, 9). In addition, other T-cell effectors patterns are involved in Mtb control in the pleural microenvironment, such as Th17, which express the retinoic acid-related orphan receptor gamma t (ROR γ t), and are characterized by secretion of large quantities of IL-17 (also known as IL-17A), IL-21, and IL-22 (9, 10). Th17 cells induce the expression of many pro-inflammatory factors, chemokines, ultimately involved in granulopoiesis and recruitment of innate cells, mainly neutrophils, especially in the early stages of infection (11, 12).

It is well described that patients at early stages of the PITB (less than 2 weeks duration) or those who present pleural effusion with high complexity (e.g., loculated pleural effusion, TB empyema) are more likely to have a neutrophilic exudate (reviewed by 13), which may contribute to injuries and decreases pleuro-pulmonary functions.

Since that the gold standard for the diagnosis of PITB which is the detection of Mtb in the sputum, pleural fluid or pleural biopsy has a discrete and variable yield, the histological demonstration of caseating granuloma even in the absence of acid-fast bacilli can be sufficient for anti-TB treatment (14, 15). Additionally, values > 40 IU/L of adenosine deaminase (ADA) in pleural effusion, a purine-degrading enzyme, associated with a predominantly lymphocytic exudate, and clinical suspicious of TB, altogether, indicates that the most likely diagnosis is tuberculosis (16, 17). However, high pleural fluid ADA values can also be found in certain conditions, such as adenocarcinoma, lymphoma, rheumatoid arthritis, and pleural empyema of bacterial etiology, making the differential diagnosis very hard (18, 19).

Considering the difficulty in the differential diagnosis already mentioned and the current knowledge about the products of the immune response against Mtb in pleural space, the present study aimed to identify biomarkers among Th1, Th2, and Th17 T-cells subsets and other inflammatory mediators in peripheral blood and pleural fluid which could present high potential of utility for the PITB diagnosis among exudative pleural effusion from other etiologies. Based on a principal component analysis (PCA), we could demonstrate a pattern of mediators which was able to discriminate TB from non-TB pleural effusion.

MATERIAL AND METHODS

Study population and settings. Patients aged ≥ 18 years with pleural effusion under investigation with thoracentesis indication were recruited in this cross-sectional prospective study which was conducted at the Pulmonology and Tisiology Service, Pedro Ernesto University Hospital/Rio de Janeiro State University (HUPE/UERJ), a tertiary care center at Rio de Janeiro, RJ, Brazil. Patients who were under 18 years of age, pregnant, or refused consent were not recruited. Of 49 recruited patients, 10 were excluded: 8 patients had transudative pleural effusion (cardiac or renal failure), and 2 patients were HIV-seropositive. Thus, 39 patients with exudative pleural effusion were enrolled in the study: 22 PITB and 17 non-TB (NTB) patients. ***PITB cases*** were defined by the patient history reviewed, followed by a detailed physical examination, and at least one diagnostic criteria: i) positive results in the microbiological and/or histopathological tests (acid-fast bacilli smear microscopy, mycobacterial culture, or Xpert MTB/RIF®) on pleural fluid or pleural tissue; ii) presence of granuloma with or without caseous necrosis; iii) clinical manifestations suggesting TB (fever, pain, dyspnea, cough, night sweats, hyporexia, and/or weight loss) in combination with a lymphocytic pleural effusion, followed by a full recovery after at least six months of anti-TB treatment. ***Non-TB cases*** consisted of patients with pleural or pleuro-pulmonary diseases, excluding active TB based on clinical, laboratory, radiological, microbiological and/or pathological features. Malignant pleural effusions were diagnosed by a positive pleural fluid cytology result or malignant cells identified in the pleural fragment. Even when both of these tests results were negative, malignant effusion was diagnosed when a primary cancer was known to have disseminated and no other cause of pleural effusion was identified. Patients who did not fit the criteria used for PITB diagnosis as above and with unknown cause of pleural effusion were classified as “undefined” pleural effusion and considered as non-PITB.

Medical information, peripheral blood, and pleural fluid sample collection were obtained from all study subjects after signing a written consent. The study protocol was approved by the respective institutional ethics committee (HUPE/UERJ; number 1.100.772).

Sample collection. Ultrasound-guided thoracentesis was performed by a trained pulmonologist who collected pleural fluid which was directly drawn into collection tubes for routine diagnostic tests, including chemistry panel, total, and differential cell count, ADA measurement by Hermes Pardini laboratory according Giusti's method (20), cytopathology, microbiological analysis (bacteria, fungi and mycobacteria), and inflammatory biomarkers for the purpose of the present study. During collection, whole blood and pleural fluid were sampled in appropriated collection tubes without anticoagulant additive. After collection, whole blood and pleural fluid tubes were centrifuged at 1000 x g for 10 min and 25 °C or 4 °C, respectively. Then, serum and pleural fluid (without cells) samples were aliquoted and stored frozen at -20 °C until cytokines quantification.

Cytokines assays. Cytokine levels in clinical samples were assessed using the following commercially available kits: i) human Th1/Th2/Th17 Cytokine Kit (BD Bioscience, San Jose, CA, USA) based on the principle of cytometric bead array (CBA) technology for simultaneous detection of seven cytokines (IL-2, IL-4, IL-6, IL-10, TNF, IFN- γ , and IL-17A). Briefly, capture beads labeled with distinct fluorescence intensity (allophycocyanin; APC) conjugated to specific antibodies for cytokines were incubated around 3 hours in the dark at room temperature with the undiluted samples, and fluorescent detection antibody (phycoerythrin; PE). All unbound antibodies were washed and samples acquired on a BD fluorescence-activated cell sorting (FACS) analyzer FACSCanto II. Cytokine standard curves ranged 0-5,000 pg/mL. ii) IP-10 and TGF- β levels were measured by enzyme-linked immunosorbent assay (ELISA) sandwich using

human CXCL-10/IP-10 DuoSet ELISA (R&D Systems Inc, MN, USA) and human/mouse TGF beta 1 ELISA Ready-SET-Go! Kit (2nd Generation; Affymetrix, eBioscience), respectively, following the manufacturer's instruction. The range of these assays was 31.3-20,000 pg/mL for IP-10 and 15.6-1,000 pg/mL for TGF- β . Readings greater than the upper limit were set at 20,000 (IP-10) or 1,000 (TGF- β) pg/mL for the purpose of analysis.

Statistical analysis. For the description of the population included in the study, according to their sociodemographic and clinical characteristics among the individuals with exudative pleural effusion due to PITB or other causes (non-TB), non-parametric Mann-Whitney test were used for continuous variables or Fisher's exact tests for comparison of the relative frequencies of the different levels of nominal/categorical variables. In the comparison between the levels of log-transformed expression (bases 10) of proteins in peripheral blood/serum and pleural fluid (tissue effect) between individuals with or without TBPI (TB effect), the expected mean marginal values obtained from multiple linear regression (log-linear) models of fixed effects were used with the inclusion of first-order interactions between the main tissue and TB effects. For the adjusted models, graphical analysis of residuals was performed to confirm their randomness. In the comparisons between expected mean marginal values obtained from linear regression models, adjustments of the confidence level were made by Sidak's method, and p-value adjustments by multiple comparisons by Tukey's method. Finally, for log10-transformed protein and ADA expression data, a multivariate principal component analysis (PCA) was performed to visualize the distribution of sample individuals in 2D dimensional spaces. Ellipses of the quantiles 68% of the normal distribution adjusted to the individuals of the different interest groups in these new dimensional spaces are presented. The level of significance, $P \leq 0.05$, was used in the analysis, and all analyses were performed in R software version 3.5.2.

RESULTS

Patients and characteristics. Study population was composed by 39 individuals who were diagnosed as PITB (n = 22) or non-TB (n = 17) according previously described. Their sociodemographic and clinical data are shown in Table 1. We observed a significant difference between the age distributions between the groups, which presented medians corresponding to 65 years (IQR: 20) in the non-TB group, and 41 years (IQR: 14) in the PITB group ($p < 0.0001$). Smoking and alcoholic habits among participants did not show statistical differences. Similarly, symptoms presentation was not dissimilar among groups. Fourteen (82%) patients in the non-TB group had one or more comorbidities, showing that this group had a significantly higher number of patients with comorbidities than observed in the PITB group, which had 4 individuals (18%) with others diseases ($p = 0.0217$). The most prevalent comorbidity was hypertension, which was reported in 6 (35%) non-TB patients and 2 (9%) PITB patients. Among non-TB patients, 13 were malignancies, 1 autoimmune disease (systemic lupus erythematosus), and 3 undefined pleural effusion.

Table 1. Sociodemographic and clinical characteristics of the study population.

Characteristics /Group	Non-TB (n=17)	PITB (n=22)	p-value
Age, years median (IQR)	65 (14)	41 (20)	0.0001
Gender (%)			
Female	7 (17.9)	8 (20.5)	1
Male	10 (25.6)	14 (35.9)	
Current smoker (%)	2 (5.1)	3 (7.7)	0.2836
Alcohol use (%)	2 (5.1)	9 (23.1)	0.1032
Comorbidities (%)	10 (25.6)	4 (10.3)	0.0172
Hypertension	6 (15.4)	2 (5.1)	0.059
Diabetes	3 (7.7)	0 (0)	0.0744
Cardiac Insufficiency	3 (7.7)	0 (0)	0.0744
Hepatitis	2 (5.1)	1 (2.6)	0.5703
Symptoms (%)			
Fever	3 (7.7)	9 (23.1)	0.1612
Cough	13 (33.3)	9 (23.1)	0.0516
Chest Pain	5 (12.8)	10 (25.6)	0.5
Dyspnea	13 (33.3)	12 (30.8)	0.3068
Night Sweats	3 (7.7)	4 (10.3)	1
Definitive cause of PE (%)			
Tuberculosis		22 (56.4)	
Malignancy	13 (33)		
Autoimmune disease	1 (2.5)		
Undefined	3 (7)		

PITB, Pleural tuberculosis; PE, pleural effusion; IQR, Interquartile range. Values expressed as n (%; from the total population) unless otherwise stated.

Cytokines measurement in blood and pleural fluid from PITB and non-TB patients. In order to evaluate the potential diagnosis of cytokines Th1/Th2/Th17, IP-10 chemokine, and ADA in exudative cases of pleural effusion, serum and pleural fluid samples from PITB and non-TB patients were analyzed. As recently reported by our group (7) and others (21–23), IFN- γ and IP-10 levels were significantly increased ($p < 0.0001$ in both) in pleural fluid comparison to serum

in PITB group (Figure 1A and H). As shown in Figure 1B, TNF concentration also showed a significant increase in the pleural fluid when compared to serum in PITB patient ($p = 0.0016$).

When these cytokines were compared with discriminatory objectives between PITB and non-TB patients, we predominantly observed significant differences in pleural fluid. IL-6 and IL-10 levels presented the same behavior when serum and pleural fluid were compared in PITB or non-TB groups (Figure 1G and E, respectively). Both IL-10 and IL-6 concentrations show that patients in both PITB ($p < 0.0001$ in both) and NTB ($p < 0.0001$ in both) groups show increased concentrations of this cytokine in pleural fluid when compared to serum in their respective groups. As expected, ADA levels were significantly higher in pleural fluid of PITB patients compared to non-TB ($p < 0.0001$). Interestingly, TGF- β concentrations were significantly higher in the serum ($p < 0.0001$) and pleural fluid of PITB patients, compared to concentrations found in non-TB patient samples ($p < 0.0001$). Concentrations of this growth factor showed no significant serum and pleural fluid difference when compared in the same group (Figure 1I).

Finally, IFN- γ , TNF, IP-10, TGF- β and ADA concentrations in the pleural fluid presented a differentiated profile between PITB and non-TB patients. Cytokines IL-17A, IL-4, and IL-2 did not show significant differences in their concentrations.

Figure 1. Cytokines and ADA levels in serum and pleural fluid from PITB and NTB patients. Cytokines were dosed by CBA (IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-17A). The levels obtained from each cytokine were analyzed on a logarithmic (base = 10) scale and illustrated using boxplots to compare serum (S) and pleural fluid (LP) data between the non-TB (NTB) and TBPI groups. The small grey dots represent individual cases and the boxplots represent the interquartile range and the median of the sample (solid grey central line). Larger

black dots and vertical bars represent expected mean marginal values estimated by the linear model and its 95% confidence intervals (95% CI). Comparisons of means between groups were performed by contrasts/differences obtained after linear bi and multivariate models, adjusted by regressions by ordinary least squares. * $p < 0.05$; ** $p < 0.01$.

Principal component analysis of pleural fluid cytokines. Finally, it was observed whether the overall cytokines profile was able to discriminate PITB and non-TB cases. In the principal components analysis (PCA), 57.21% of the total variance in response to 9 cytokines and biomarkers was expressed by 2 principal components (Table 2; Figure 2). The first component accounted for a total of 40.58%, while the second accounted for 16.63% of the total variance (Figure 2). Altogether, these 9 cytokines were able to discriminate between PITB and non-TB. The most determinant variables of each of these two principal components were respectively ADA, IP-10, TGF- β , IFN- γ , and TNF, for the first principal component (PC1), and IL17A, IL-4, and IL-2 for the second principal component (PC2).

Table 2. Principal components analysis.

Component	Eigenvalue	Difference	Proportion	Cumulative
Component 1	3.95	2.33	40.58	40.58
Component 2	1.62	0.31	16.63	57.21
Component 3	1.32	0.42	13.50	70.70
Component 4	0.90	0.10	9.22	79.92
Component 5	0.79	0.30	8.16	88.08
Component 6	0.50	0.15	5.08	93.16
Component 7	0.35	0.10	3.55	96.71
Component 8	0.24	0.16	2.48	99.19
Component 9	0.08	0.07	0.79	99.98
Component 10	0.00	NA	0.02	100.00

Variable	Component 1	Component 2
ADA	-0.41429	-0.21968
IP-10	-0.44817	-0.19145
TGF- β	-0.4445	-0.18435
IL17A	-0.0793	0.394041
IFN- γ	-0.44469	-0.18198
TNF	-0.38718	0.253531
IL-10	-0.1654	0.330127
IL-6	-0.03609	-0.02504
IL-4	-0.16608	0.56734
IL-2	-0.1405	0.443796

Principal component analysis of inflammatory biomarkers in pleural fluid from patients with pleural effusion by pleural tuberculosis and other diagnoses. Shaded values represent the most important biomarkers in the component definition. NA: not applicable.

Figure 2. A pattern of inflammatory biomarkers in pleural fluid discriminates PITB from NTB patients. The analysis of variance of cytokine concentrations by CBA (IL-2, IL-4, IL-6, IL-10, TNF, IFN- γ , and IL-17A) and ELISA (TGF- β and IP-10) ADA were evaluated by the PCA method, with the objective to finding heterogeneity between the cytokine profile of patients with pleural tuberculosis (PITB) and other diagnoses non-TB (NTB). Two components were used to explain most of the total variation of these data.

DISCUSSION

Among many known causes of pleural effusion, heart failure, malignant conditions, pneumonia, and PITB are responsible for three-quarters of all cases (24). Currently, there is scarce literature comparing PITB with other causes of exudative pleural effusions, which contributes to the difficulty of establishing criteria for the differential diagnosis of PITB. The present study sought to find elements that are capable of differentiating the tuberculous effusion from other agents causing pleural effusion. Analyzing the pleural microenvironment, the quantification of cytokines showed higher concentrations of IFN- γ , TNF, TGF- β , IP-10 and ADA in LP of PITB patients, when compared to LP of non-TB patients. Analysis of principal components revealed that these cytokines and inflammatory mediators showed the largest variations associated with a partial distinction between PITB and non-TB patients.

As mentioned, ADA dosage is routinely used as a marker of PITB, although it does not define the differential diagnosis (17, 18). As for the general characteristics of pleural effusions, as expected, the median value corresponding to ADA concentrations was significantly higher in the PITB group, compared to the non-TB group. Although very useful in the differentiation of tuberculous effusion, several authors diverge about the true diagnostic value of the ADA, often setting other cutoff values. However, although they are found in greater amounts in the pleural fluid, these mediator have not been used, alone, as differential markers in exudative pleural effusions. In a recent work published by our group (7), we proposed a model where the values of IP-10, IFN- γ , and ADA in a revised cutoff value, analyzed together, can be used in the differential diagnosis of PITB with high performance in microbiologically unconfirmed cases of PITB.

The immune system plays a pivotal role in the evolution of Mtb infection. To contain the infection, the defense cells together with inflammatory mediators generated at the site of the infection produce a potent and aggressive response, which can generate important tissue lesions (25). In addition, the direct action on the mesothelial cells and vascular endothelium, present great participation of the tissue repair and fibrosis processes, causing functional impairment of the pleural and lungs (26, 27). At the same time, an insufficient immune response may allow the multiplication and dissemination of the bacillus (25). Otherwise, the immune system products can be used to identify pleural effusions caused by TB.

Classically, the Th1 response is the most studied in TB, being responsible both for the containment of Mtb and for the tissue injury caused by the excessive response to the bacillus (reviewed by 28). As expected, Th1-related cytokines IFN- γ and TNF, as well as the biomarker IP-10, are increased in the pleural fluid of PITB patients compared to blood (Figure 1). Recently, the dosage of IFN- γ in pleural effusion raised importance as an auxiliary method for the diagnosis of PITB, becoming an example of a test used for this purpose, since this cytokine is at high levels during the active phase of the disease (23, 28). The IFN- γ -release assay (IGRA) has also been highlighted in this context. The test evaluates the activity of T lymphocytes under stimulation of Mtb ESAT-6 and CFP-10 antigens. However, as reviewed by Aggarwal and collaborators (2015) there are many conflicting results regarding this diagnostic method of active tuberculosis, both in pulmonary and pleural forms (29). Moreover, as recently delineated by our group, IGRA has a poor meaning in PITB (7), perhaps due to their paucibacillary nature or due to the enrichment of inflammatory mediators in pleural space, without needing of an additional antigen-stimuli. TNF is another important mediator in the response against Mtb and it is directly related to the maintenance of the granuloma structure, maintaining the colonization of the bacillus and necrosis area in a restricted manner (30). Other evidence shows that patients treated with an anti-TNF

antibody developed active tuberculosis after reactivation of latent infection (31). In addition, TNF is important in the intracellular control of Mtb (Review by 25). Li et al. (2014) found a higher diagnostic value in TNF measurements than that found in ADA values (22). IP-10 is well studied as a possible biomarker in TB and is directly associated with INF- γ since its production is mainly induced by this cytokine. As revised by Porcel (32), IP-10 is not an essential biomarker for the PITB diagnosis but has been the subject of several studies in this context, based on its participation in the immunopathogenesis of the disease and their correlation with IFN- γ (7, 21).

Recently, the Th17 response also gained prominence in the immunopathology of tuberculosis, especially in the early stages of infection (9, 10). Particularly in PITB, Ye et al. (2011) showed an increase of lymphocytes with Th17 profile in pleural fluid compared to blood. Our results, presented here, show high concentrations of IL-6 and TGF- β in pleural fluid of PITB patients compared to serum (34). These two biomarkers are critical in the differentiation of Th17 cells (35). Therefore, although our study did not focus on the characterization of Th17 cells, it is quite probable that the microenvironment, through the high concentration of IL-6, TGF- β , and the low concentrations of IL-2 is favoring the differentiation of this T-lymphocytes effector phenotype in the PLTB group.

IL-10 is a cytokine involved in the suppression of the immune response (36). In the case of TB, it has been associated with suppression of dendritic cell activity, the formation of foamy macrophages and defective formation of granuloma (37–39). The production of IL-10 is one of the more classic mechanisms of suppression by T regulatory cells, however, this cytokine can be produced by many other cells of the immune system, such as macrophages, B lymphocytes and Th2 lymphocytes (40). Our study has shown higher concentrations of IL-10 in the pleural fluid of patients with PITB compared to serum, and in the same way in the NTB group. However, the methodology used in this study was not able to identify which cells present in the pleural fluid

were responsible for the increase of IL-10 concentrations, as well as the other cytokines. Geffner et al. (2013) showed an increased IL-10 production after stimulation of mononuclear cells in pleural fluid and peripheral blood with Mtb antigens, and decrease of this cytokine after removal of culture Treg cells provides evidence that Treg is also responsible for the production of IL-10 from the pleural cavity (41).

The cytokine pattern related to the Th2 effector phenotype was also evaluated. In the methodology employed, but did not detect significant levels of IL-4. This finding confirms the literature data that show little influence of this effector phenotype in cases of tuberculosis (2, 33), although IL-4 concentrations in miliary TB have already been reported (5).

Another important finding in our study was the quantification of TGF- β in serum and pleural fluid. This growth factor, secreted by monocytes, is a chemotactic agent for fibroblasts, plays an important role in extracellular matrix remodeling (42). One of the possible contributions of TGF- β to the pathophysiology of PITB is its ability to induce fibrosis, as shown in the study by Sasse et al (2003), where animals infected with Mtb showed increased pleural thickening in proportion to the increase in TGF- β (43). Seiscento et al (2007) also found elevated TGF- β levels in serum and pleural fluid of PITB patients, associating with the degree of pleural thickening in these patients (44). Our findings, together with the evidence found in the literature, reinforce the hypothesis that this mediator may be related to the development of pleural effusions in TBP1 patients since TGF- β levels were found to be significantly higher in the pleural fluid of these patients, compared to the results found in non-TB patients. Although the cited studies found a significant increase of TGF- β in pleural fluid and serum, the comparison group in the experimental model of these studies was composed of patients with transudative pleural effusion. Our work was able to detect the increase of TGF- β in the serum and pleural fluid of PITB patients, compared to blood and pleural fluid in patients with other causes of exudative effusion.

This finding may contribute to future investigations, associating TGF- β as a possible biomarker to aid in the differential diagnosis of PITB.

In fact, the cytokines analyzed alone are not able to provide data of high specificity and sensitivity, especially in comparison to exudative effusions. However, when analyzed together, they can provide high diagnostic value (7, 22). Therefore, in the present study, PCA was performed in an attempt to establish a pattern of cytokines and mediators in blood and pleural fluid capable of discriminating the PITB and non-TB cases. Our results show that 9 cytokines and biomarkers, measured in blood and pleural fluid, were reduced to two principal components (Table 2). Together, they were able to discriminate the PITB and non-TB cases and explained 57% of the variation. The cytokines with determinant values were ADA, TGF- β , IP-10, IL-17A, IFN- γ , TNF, IL-4, and IL-2. These results provide new data in the search for new markers capable of differentiating the causes of exudative pleural effusion.

Some limitations should be considered in our study. First, it was conducted in a single-center, imposing a validation in other reference centers and in different populations. Another consideration is regarding the relatively low number of patients included per group. However, patients were included prospectively, in a real routine of clinical practice in a tertiary reference center which reflected in variable clinical characteristics inherent of each group of study, as can be observed in Table 1. Moreover, we have analyzed only exudative cases of pleural effusion, the main confounders in the differential diagnosis of TB. Also, we have excluded transudative cases which could add some bias in our analysis.

In summary, the analysis of a panel of inflammatory mediators previously highlighted in the TB literature was useful to provide new hypotheses and better comprehension about microenvironment of the pleural cavity during the immunopathology of Mtb infection. In addition, the screening in pleural fluid identified biomarkers with high potential for use alone or

in combination, which is able to increase the sensitivity of diagnosis and prompt the TB treatment, especially in cases of hard identification and distinction by conventional diagnostic methods.

Acknowledgments

We would like to thank the physicians of Tuberculosis Outpatient Clinics of HUPE/UERJ, which contributed to the medical care of the patients included in the study.

Author Contributions

Conceptualization: Luciana Silva Rodrigues.

Data curation: Vinicius da Cunha Lisboa, Raquel da Silva Corrêa, Isabelle Ramos Lopes.

Formal analysis: Vinicius da Cunha Lisboa, Raquel da Silva Corrêa, Marcelo Ribeiro-Alves.

Funding acquisition: Thaís Porto Amadeu, Rogério Lopes Rufino Alves, Luciana Silva Rodrigues.

Investigation: Vinicius da Cunha Lisboa, Thiago Thomaz Mafort, Ana Paula Gomes dos Santos, Rogério Lopes Rufino Alves, Luciana Silva Rodrigues.

Methodology: Vinicius da Cunha Lisboa, Raquel da Silva Corrêa, Isabelle Ramos Lopes.

Project administration: Luciana Silva Rodrigues.

Resources: Rogério Lopes Rufino Alves, Luciana Silva Rodrigues.

Software: Vinicius da Cunha Lisboa, Marcelo Ribeiro-Alves.

Supervision: Luciana Silva Rodrigues.

Validation: Marcelo Ribeiro-Alves.

Writing – original draft: Vinicius da Cunha Lisboa, Raquel da Silva Corrêa, Marcelo Ribeiro-Alves, Luciana Silva Rodrigues.

Writing – review & editing: Vinicius da Cunha Lisboa, Marcelo Ribeiro-Alves, Luciana Silva Rodrigues.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: This work was supported by the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (Grant No: 261101792014), (Website: <http://www.faperj.br/>). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

References

1. World Health Organization. | Global tuberculosis report 2018. WHO. 2019.
2. Vorster MJ, Allwood BW, Diacon AH, Koegelenberg CFN. 2015. Tuberculous pleural effusions: Advances and controversies. *J Thorac Dis* 7:981–991.
3. Gomes T, Reis-Santos B, Bertolde A, Johnson JL, Riley LW, Maciel EL. 2014. Epidemiology of extrapulmonary tuberculosis in Brazil: a hierarchical model. *BMC Infect Dis* 14:9.
4. Seibert AF, Haynes J, Middleton R, Bass JB. 1991. Tuberculous Pleural Effusion. *Chest* 99:883–886.
5. Sharma SK, Mitra DK, Balamurugan A, Pandey RM, Mehra NK. 2002. Cytokine polarization in miliary and pleural tuberculosis. *J Clin Immunol* 22:345–52.
6. Mitra DK, Sharma SK, Dinda AK, Bindra MS, Madan B, Ghosh B. 2005. Polarized helper T cells in tubercular pleural effusion: phenotypic identity and selective recruitment. *Eur J Immunol* 35:2367–75.
7. Santos AP, Corrêa R da S, Ribeiro-Alves M, Soares da Silva ACO, Maforé TT, Leung J, Pereira GMB, Rodrigues LS, Rufino R. 2018. Application of Venn’s diagram in the diagnosis of pleural tuberculosis using IFN- γ , IP-10 and adenosine deaminase. *PLoS One* 13:e0202481.
8. Luckheeram R, Zhou R, Verma A, Xia B. 2012. CD4⁺T Cells: Differentiation and Functions. *Clin Dev Immunol* 2012:1–12.
9. Lyadova I V., Panteleev A V. 2015. Th1 and Th17 Cells in Tuberculosis: Protection, Pathology, and Biomarkers. *Mediators Inflamm* 2015.
10. Wang T, Lv M, Qian Q, Nie Y, Yu L, Hou Y. 2011. Increased frequencies of T helper type 17 cells in tuberculous pleural effusion. *Tuberculosis (Edinb)* 91:231–7.

11. Burkett PR, Zu Horste GM, Kuchroo VK. 2015. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. *J Clin Invest* 125:2211–2219.
12. Korn T, Bettelli E, Oukka M, Kuchroo VK. 2009. IL-17 and Th17 Cells. *Annu Rev Immunol* 27:485–517.
13. Shaw JA, Irusen EM, Diacon AH, Koegelenberg CF. 2018. Pleural tuberculosis: A concise clinical review. *Clin Respir J* 12:1779–1786.
14. Diacon AH, Van de Wal BW, Wyser C, Smedema JP, Bezuidenhout J, Bolliger CT, Walzl G. 2003. Diagnostic tools in tuberculous pleurisy: a direct comparative study. *Eur Respir J* 22:589–91.
15. Gopi A, Madhavan SM, Sharma SK, Sahn SA. 2007. Diagnosis and Treatment of Tuberculous Pleural Effusion in 2006. *Chest* 131:880–889.
16. Lee SJ, Lee SH, Lee TW, Lee HR, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim HS. 2014. Factors Influencing Pleural Adenosine Deaminase Level in Patients With Tuberculous Pleurisy. *Am J Med Sci* 348:362–365.
17. Jiménez Castro D, Díaz Nuevo G, Pérez-Rodríguez E, Light RW. 2003. Diagnostic value of adenosine deaminase in nontuberculous lymphocytic pleural effusions. *Eur Respir J* 21:220–4.
18. Greco S, Girardi E, Masciangelo R, Capocchetta GB, Saltini C. 2003. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a meta-analysis. *Int J Tuberc Lung Dis* 7:777–86.
19. Valdés L, San José E, Alvarez D, Valle JM. 1996. Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. *Eur Respir J* 9:747–51.
20. Giusti G. 1974. Adenosine deaminase, p. 1092–99. *In* Bergmeyer, H-Ui (ed.), *Methods of*

enzymatic analysis 2nd editio. New York: Academic Press, New York.

21. Ruhwald M, Aabye MG, Ravn P. 2012. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. *Expert Rev Mol Diagn* 12:175–187.
22. Li M, Wang H, Wang X, Huang J, Wang J, Xi X. 2014. Diagnostic accuracy of tumor necrosis factor-alpha, interferon-gamma, interleukine-10 and adenosine deaminase 2 in differential diagnosis between tuberculous pleural effusion and malignant pleural effusion. *J Cardiothorac Surg* 9:118.
23. Porcel JM. 2016. Advances in the diagnosis of tuberculous pleuritis. *Ann Transl Med* 4:282.
24. Porcel JM, Esquerda A, Vives M, Bielsa S. 2014. Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas. *Arch Bronconeumol* 50:161–165.
25. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR. 2013. The immune response in tuberculosis. *Annual review of immunology*.
26. Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. 2006. The resumption of consumption - A review on tuberculosis. *Mem Inst Oswaldo Cruz* 101:697–714.
27. Shirakihara T, Saitoh M, Miyazono K. 2007. Multiple pathways differentially regulate global oxidative stress responses in fission yeast. *Mol Biol Cell* 18:3533–3544.
28. Arrigucci R, Lakehal K, Vir P, Handler D, Davidow AL, Herrera R, Estrada-Guzmán JD, Bushkin Y, Tyagi S, Lardizabal AA, Gennaro ML. 2018. Active Tuberculosis Is Characterized by Highly Differentiated Effector Memory Th1 Cells. *Front Immunol* 9:2127.
29. Meldau R, Peter J, Theron G, Calligaro G, Allwood B, Symons G, Khalfey H, Ntombenhle G, Govender U, Binder A, van Zyl-Smit R, Dheda K. 2014. Comparison of same day

- diagnostic tools including Gene Xpert and unstimulated IFN- γ for the evaluation of pleural tuberculosis: a prospective cohort study. BMC Pulm Med 14:58.
30. Aggarwal AN, Agarwal R, Gupta D, Dhooria S, Behera D. 2015. Interferon Gamma Release Assays for Diagnosis of Pleural Tuberculosis: a Systematic Review and Meta-Analysis. J Clin Microbiol 53:2451–2459.
31. Clay H, Volkman HE, Ramakrishnan L. 2008. Tumor Necrosis Factor Signaling Mediates Resistance to Mycobacteria by Inhibiting Bacterial Growth and Macrophage Death. Immunity 29:283–294.
32. Bruns H, Meinken C, Schauenberg P, Härter G, Kern P, Modlin RL, Antoni C, Stenger S. 2009. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 119:1167–77.
33. Porcel JM. 2018. Biomarkers in the diagnosis of pleural diseases: a 2018 update. Ther Adv Respir Dis 12:1753466618808660.
34. Ye Z-J, Zhou Q, Du R-H, Li X, Huang B, Shi H-Z. 2011. Imbalance of Th17 cells and regulatory T cells in tuberculous pleural effusion. Clin Vaccine Immunol 18:1608–15.
35. Bhaumik S, Basu R. 2017. Cellular and Molecular Dynamics of Th17 Differentiation and its Developmental Plasticity in the Intestinal Immune Response. Front Immunol 8:254.
36. Couper K, Blount D, Riley E. 2008. IL-10: the master regulator of immunity to infection. J Immunol 180:5771–5777.
37. Abdalla AE, Lambert N, Duan X, Xie J. 2016. Interleukin-10 Family and Tuberculosis: An Old Story Renewed. Int J Biol Sci 12:710–7.
38. Cyktor JC, Carruthers B, Kominsky RA, Beamer GL, Stromberg P, Turner J. 2013. IL-10 inhibits mature fibrotic granuloma formation during Mycobacterium tuberculosis infection. J Immunol 190:2778–90.

39. Genoula M, Marín Franco JL, Dupont M, Kviatcovsky D, Milillo A, Schierloh P, Moraña EJ, Poggi S, Palmero D, Mata-Espinosa D, González-Domínguez E, León Contreras JC, Barrionuevo P, Rearte B, Córdoba Moreno MO, Fontanals A, Crotta Asis A, Gago G, Cougoule C, Neyrolles O, Maridonneau-Parini I, Sánchez-Torres C, Hernández-Pando R, Vérollet C, Lugo-Villarino G, Sasiain MDC, Balboa L. 2018. Formation of Foamy Macrophages by Tuberculous Pleural Effusions Is Triggered by the Interleukin-10/Signal Transducer and Activator of Transcription 3 Axis through ACAT Upregulation. *Front Immunol* 9:459.
40. Redford PS, Murray PJ, O'Garra A. 2011. The role of IL-10 in immune regulation during *M. tuberculosis* infection. *Mucosal Immunol* 4:261–270.
41. Geffner L, Basile JJ, Yokobori N, Sabio Y, García C, Musella R, Castagnino J, Sasiain MC, de la Barrera S. 2014. CD4(+) CD25(high) forkhead box protein 3(+) regulatory T lymphocytes suppress interferon- γ and CD107 expression in CD4(+) and CD8(+) T cells from tuberculous pleural effusions. *Clin Exp Immunol* 175:235–45.
42. Toossi Z, Ellner JJ. 1998. The Role of TGF β in the Pathogenesis of Human Tuberculosis. *Clin Immunol Immunopathol* 87:107–114.
43. Sasse SA, Jadus MR, Kukes GD. 2003. Pleural Fluid Transforming Growth Factor- β 1 Correlates with Pleural Fibrosis in Experimental Empyema. *Am J Respir Crit Care Med* 168:700–705.
44. Seiscento M, Vargas FS, Antonangelo L, Acencio MMP, Bombarda S, Capelozzi VL, Teixeira LR. 2007. Transforming growth factor β -1 as a predictor of fibrosis in tuberculous pleurisy. *Respirology* 12:660–663.